恆發光學(01134.HK)擬收購湖南妙盛出行科技51%股權
格隆匯1月28日丨恆發光學(01134.HK)發佈公吿,於2021年1月28日,恆發光學有限公司(為公司全資附屬公司)與深圳康順新能源汽車有限公司(賣方)及龍愛國訂立不具法律約束力的諒解備忘錄。據此,附屬公司有意收購湖南妙盛出行科技有限公司(目標公司)51%股權。
目標公司於中國成立,主要從事經營新能源汽車充電站;及提供網上預約汽車服務。根據賣方及龍先生所提供的資料,目標公司已開發單次充電續航里程領先的新能源汽車的新型電池及電機和控制系統。於本公吿日期,目標公司由賣方擁有80%權益,而賣方則由龍先生全資擁有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.